Aspiring Healthcare Stock Secures Support from Former Macquarie CEO for ASX IPO

2 min read | November 29, 2024 04:19 AM GMT | By Team Kalkine Media

Highlights:

  • HaemaLogiX, an Australian biotech focused on blood cancer treatments, is preparing for an ASX IPO in 2025.

  • The company has already raised significant funding, including a pre-IPO capital raise.

  • HaemaLogiX is advancing its CAR-T immunotherapy, with its first human trial set to begin in 2025.

HaemaLogiX, an Australian biotechnology company specializing in blood cancer treatments, is gearing up for an Initial Public Offering (IPO) on the Australian Securities Exchange (ASX) in 2025. The company, which counts former Macquarie Group (ASX:MQG) CEO Allan Moss and Platinum Asset Management among its shareholders, has enlisted Jefferies and Ord Minnett to support its IPO preparations. The company hopes to raise a substantial amount from the offering, which is planned for the second quarter of the new year.

As a private entity, HaemaLogiX has already raised $24.1 million and is currently undertaking a pre-IPO capital raise. The company aims to secure between $15 million and $20 million by mid-December. These funds are crucial for advancing its clinical trials and further developing its innovative therapies.

HaemaLogiX focuses on addressing blood cancers such as multiple myeloma, a type of bone marrow cancer that affects a significant number of Australians. The company is collaborating with the renowned Peter MacCallum Cancer Centre to conduct the first human trial of its CAR-T immunotherapy, KMA.CAR-T, specifically for kappa-type multiple myeloma. The first patient is expected to be treated in the second quarter of 2025, marking a key milestone in the company's clinical development.

In addition to its work in cancer treatment, HaemaLogiX is also exploring the potential of its therapies for autoimmune diseases, including amyloidosis. The funds raised through the upcoming capital raise will primarily support the fourth clinical trial of HaemaLogiX's KappaMab immunotherapy, which has shown promising results in prior trials.

HaemaLogiX's leadership includes Dr. Rosanne Dunn, Bryce Carmine, and board chair Dr. John Cullity. The company's managing director, Damian Clarke-Bruce, has experience leading other biotech firms, further bolstering confidence in HaemaLogiX's future prospects. With 75 patent filings and a strong commitment to innovative treatments, HaemaLogiX is positioning itself as a significant player in the Australian healthcare sector.

 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next